What to do if you become resistant to Regorafenib

Regorafenib (Regorafenib) is a multi-target anti-cancer drug commonly used to treat advanced colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. However, sometimes patients may develop resistance to regorafenib. Doctors will make sure that resistance is not caused by other factors, such as changes in tumor type or other foreign bodies,and determine whether there are genetic mutations associated with resistance through molecular testing techniques (such as genome sequencing).

Doctors may alsoconsider the use of regorafenib in combination with other drugs,possibly combining regorafenib with other anticancer drugs, radiation therapy, or immunotherapy, In order to increase the therapeutic effect, or under the guidance of a doctor, adjusting the dose or dosage regimen of regorafenib may help to overcome drug resistance. Patients can find clinical trials that are right for their situation. Sometimes new drugs or treatments may be under investigation and may be available as experimental treatment options.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).